More focus, greater impact
We’ve streamlined our work by developing new innovative medicines for a core group of illnesses: cancer, gastro-intestinal, infection, respiratory and inflammation, neuroscience and cardiovascular.
In the UK, we invest around £1 billion each year in research and development, and through collaborations with the healthcare industry and its patients, we’re developing even more targeted medicines.
Cardiovascular & Diabetes
Cardiovascular diseases, including coronary heart disease and acute coronary syndrome, kill one in three people in the UK each year1. It is estimated that around 10% of the NHS budget is spent on diabetes2
In the West (i.e. Europe and North America) between 10-20% of adults suffer from gastro-oesophageal reflux disease (GORD)3.
Increasingly resistant to antibiotics, many infectious diseases continue to be a risk to global health.
UK cancer rates are expected to rise 45% by 20304, making our work in this area increasingly important.
Our innovations in neuroscience include anesthetic treatments and medicines for mental illness and headaches disorders.
Respiratory & Inflammation
Over 5.4 million people in the UK have asthma5; so developing new treatments for this and other respiratory diseases is vital to improving lives.
726112 March 2013